Skip to main content

Advertisement

SpringerLink
Log in

The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage

  • Original Article
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Background

Activated prothrombin complex concentrates factor eight inhibitor bypassing activity (FEIBA) has been recommended for reversing novel oral anticoagulants (NOAC) in the context of intracerebral hemorrhage (ICH), though few clinical studies report its use.

Methods

A prospective study of patients with spontaneous ICH was conducted from May 2013 to May 2015. Hospital complications including hemorrhage (gastrointestinal bleeding, anemia requiring transfusion, and surgical site bleeding) and thrombosis (pulmonary embolus, deep vein thrombosis, ischemic stroke, and myocardial infarction) were recorded. All ICH patients underwent baseline head CT and a follow-up stability scan in 6 h. NOAC taken within 48 h of presentation was reversed with FEIBA (50 u/kg) per protocol. Three-month outcomes were assessed using the modified rankin score (mRS).

Results

Of 127 ICH patients enrolled, 6 (5 %) had NOAC-related ICH including: oral factor XA inhibitor N = 5 (4 %; N = 4 rivaroxaban, N = 1 apixaban] and direct thrombin inhibitor N = 1 (0.8 %; dabigatran). The indication for NOAC was atrial fibrillation in all patients and the median CHADS2–VASC score was 4 (range 2–5). The median admission NIHSS was 2 (range 0–14) and the median ICH volume was 8 mL (range 1–20). Five patients (3 rivaroxaban, 1 apixaban, 1 dabigatran) presented within 48 h and received FEIBA within a median of 13 h (range 10–29 h) from their last NOAC dose and 8 h (range 4.5–20) from the time last known well. None of the patients had ICH expansion, hemorrhagic, or thrombotic complications. Three-month median mRS was 1 (range 0–6).

Conclusion

In this small case series, reversal of NOAC with FEIBA was not associated with ICH expansion or any thrombotic or hemorrhagic complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation. 2011;124:1982–93.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient metaanalysis. JAMA. 2003;288:2441–8.

    Article  Google Scholar 

  3. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage facts and hypotheses. Stroke. 1995;26:1471–7.

    Article  CAS  PubMed  Google Scholar 

  4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. doi:10.1056/NEJMoa0905561 published correction appears in N Engl J Med. 2010;363:1877.

    Article  CAS  PubMed  Google Scholar 

  5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. doi:10.1056/NEJMoa1009638.

    Article  CAS  PubMed  Google Scholar 

  6. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, GonzalezHermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17. doi:10.1056/NEJMoa1007432.

    Article  CAS  PubMed  Google Scholar 

  7. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486–90. doi:10.1001/jamaneurol.2013.4021.

    PubMed  Google Scholar 

  8. Hemphill JC III, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung G, Goldstein J, Macdonald L, Mitchell P, Scott P. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2032.

    Article  PubMed  Google Scholar 

  9. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004;10(Suppl 2):3–9.

    Article  CAS  PubMed  Google Scholar 

  10. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217–24.

    Article  CAS  PubMed  Google Scholar 

  11. Perzborn E, Heitmeier S, Laux V, Buchmuller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res. 2014;133(4):671–81.

    Article  CAS  PubMed  Google Scholar 

  12. Schulman S, Ritchie B, Goy JK, Nahirniak S, Almutawa M, Ghanny S. Activated prothrombin complex concentrate for dabigatran-associated bleeding. Br J Haematol. 2013;164:296–310.

    Google Scholar 

  13. Wong H, Keeling D. Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. Br J Haematol. 2014;166:140–53.

    Article  Google Scholar 

  14. Puttick T, Bahl R, Mohamedbhai H. Emergency reversal of dabigatran for emergency surgery. BMJ Case Rep. 2015. doi:10.1136/bcr-2014-209057.

    PubMed  Google Scholar 

  15. Dager W, Roberts A. Reversing dabigatran with FEIBA in a patient with a transseptal perforation during cardiac ablation. Crit Care Med. 2011;39(12):243.

    Google Scholar 

  16. Heidbuchel H, Verhamme P, Alings M, et al. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625–51.

    Article  PubMed  Google Scholar 

  17. Meyer CS, Blebea J, Davis K Jr, Fowl RJ, Kempczinski RF. Surveillance venous scans for deep venous thrombosis in multiple trauma patients. Ann Vasc Surg. 1995;9(1):109–14.

    Article  CAS  PubMed  Google Scholar 

  18. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S–77S. doi:10.1378/chest.11-2297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kiraly A, Lyden A, Periyanayagam U, Chan J, Pang P. Management of hemorrhage complicated by novel oral anticoagulants in the emergency department: case report from the northwestern emergency medicine residency. Am J Ther. 2013;20:300–6.

    PubMed  Google Scholar 

  20. Maurice-Szamburski A, Graillon T, Bruder N. Favorable outcome after subdural hematoma treated with FEIBA in a 77-year-old patient treated by rivaroxaban. J Neurosurg Anesthesiol. 2014;26:2.

    Article  Google Scholar 

  21. Lindahl TL, Wallstedt M, Gustafsson KM, Persson E, Hillarp A. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Thromb Res. 2015;135(3):544–7.

    Article  CAS  PubMed  Google Scholar 

  22. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol. 2013;35(2):222–4.

    Article  PubMed  Google Scholar 

  23. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA)-addressing safety issues. Haemophilia. 2008;14:39–43.

    Article  CAS  PubMed  Google Scholar 

  24. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8(3):280–7.

    Article  CAS  PubMed  Google Scholar 

  25. Glund S, Stangier J, Schmohl M, De Smet M, Gansser D, Lang B, Moschetti V, Ramael S, Reilly P. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation. 2013;128:A17765.

    Google Scholar 

  26. Glund S, Stangier J, Schmohl M, Moschetti V, Haazen W, Gansser M, Norris S, Lang B, Reilly P. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014;124:A344.

    Article  Google Scholar 

  27. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015. doi:10.1056/NEJMoa1502000.

    PubMed  Google Scholar 

  28. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51.

    Article  CAS  PubMed  Google Scholar 

  29. Crowther M, Vandana M, Michael K, et al. A Phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. 55th ASH annual meeting, New Orleans 2013.

  30. Crowther M, Levy G, Lu G, Leeds J, Barron L, Conley P, Castillo J, Curnutte J, Connolly S. ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alpha (PRT064445), a universal antidote for factor Xa (fXa) Inhibitors. Circulation. 2014;130:2105.

    Article  Google Scholar 

  31. Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th Congress of the International Society on Thrombosis and Haematosis, Amsterdam, June 29–July 4, 2013.

  32. Bakhru S, Laulicht B, Jiang X, Chen L, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S. PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation. 2014;128:A18809.

    Google Scholar 

  33. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141–2. doi:10.1056/NEJMc1411800.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cerebrovascular Center of the Neurological Institute, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH, 44195, USA

    Jamil R. Dibu, Jonathan M. Weimer, Christine Ahrens, Edward Manno & Jennifer A. Frontera

Authors
  1. Jamil R. Dibu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan M. Weimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Ahrens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edward Manno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jennifer A. Frontera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer A. Frontera.

Ethics declarations

Conflict of Interest

The authors have nothing to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dibu, J.R., Weimer, J.M., Ahrens, C. et al. The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage. Neurocrit Care 24, 413–419 (2016). https://doi.org/10.1007/s12028-015-0213-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-015-0213-y

Keywords

Search

Navigation